Foundayo vs. Oral Wegovy: Which GLP-1 Pill Should You Actually Take?

There are now two FDA-approved GLP-1 pills for weight loss, and they are not the same drug. Dr. Clete Barrick (board-certified in internal medicine and obesity medicine) breaks down the side-by-side: the chemistry, the dosing rules, the weight loss data, the side effects, the cost, and which patient profile fits each pill.

What you'll learn:
- Why Foundayo (orforglipron) and oral Wegovy (semaglutide 25 mg) are pharmacologically different drugs, not just two brands of the same thing
- The morning ritual oral Wegovy requires and why pharmacokinetic studies say you can't cheat it
- Trial weight loss numbers from ATTAIN-1 (Foundayo) and OASIS 4 (oral Wegovy) and what the 1.2-point gap actually means in real life
- The side effect paradox: lower nausea on Foundayo but higher discontinuation at the top dose
- May 2026 self-pay and insured pricing through LillyDirect and NovoCare
- The patient profiles where each pill is the right answer, and the case where a needle is still better than a pill

Timestamps:
0:00 — Opening
0:45 — Welcome to Straight Shot
1:00 — Why this matters now
2:30 — Shot 1: The chemistry
4:45 — Shot 2: How you take each pill
7:00 — Shot 3: How much weight comes off
9:15 — Shot 4: The side effect paradox
11:30 — GLP-1 Bible pre-order
12:00 — Shot 5: What you'll actually pay
13:00 — The Straight Shot
14:30 — Wrap & subscribe

Studies and sources referenced:
- Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). NEJM. 2025;393(18):1796-1806.
- Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). NEJM. 2025;393(11):1077-1087.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM. 2021;384(11):989-1002.
- Buckley ST et al. Transcellular stomach absorption of a derivatized GLP-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047.
- Granhall C et al. Safety and pharmacokinetics of single and multiple ascending doses of oral semaglutide. Clin Pharmacokinet. 2019;58(6):781-791.
- Foundayo (orforglipron) Prescribing Information. Eli Lilly. April 2026.
- Wegovy (semaglutide tablets) Prescribing Information. Novo Nordisk. December 2025.
- Eli Lilly. ATTAIN-MAINTAIN press release, December 18, 2025.
- LillyDirect Foundayo pricing, April 2026.
- NovoCare Wegovy pricing, April 2026.

Resources:
- Pre-order The GLP-1 Bible: barrickhealth.com
- Book a 1-on-1 consult with Dr. Barrick: barrickhealth.com
- YouTube: @BarrickHealth
- Reddit: u/CleteBarrickMD

Disclaimer: This episode is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication.

Transcript

SPEAKER_00 0:00

There are two FDA-approved GLP1 pills on the market right now. Both for weight loss, both daily, both work on the same receptor in your brain, and they are not the same drug. One produces a little more weight loss, but demands a strict morning ritual, empty stomach. A few sips of water, wait 30 minutes every single day. The other one, take it whenever. With coffee, food, with whatever you want, no rules. Patients on Reddit are calling them the strict pill and the easy pill, and the shorthand actually fits. Today I'll tell you what these two pills really are, who each one is built for, and the trade-off you are actually making when you pick one. I'm Dr. Cleet Berrick, dual board certified in internal medicine and obesity medicine. I've treated thousands of patients on GLP1 medications, peptides, and medical weight loss therapy. This is Straight Shot, the science of weight loss explained by a doctor who lives it. Quick note: everything on this show is for education only. It is not medical advice for your specific situation. Always talk to your prescribing physician before making any changes to your treatment. Welcome to Street Shot. Here is where we are in May 2026. Oral Wagovy launched in December. Within the first week, it was prescribed over 18,000 times, a stronger debut than the injectable got back in 2021. Foundayo, the brand name for orforklipron, from Eli Lilly, got FDA approved in April of this year. So this is a brand new. The first time in history a patient walks into my office and says, I want a GLP1 pill, and I actually have some real choices to make. The marketing makes these two drugs look interchangeable. Both pills, both daily, both for weight loss. They are not interchangeable. Different molecules, different absorption, different rules, different efficacy, side effect profiles, same target, everything else, a fork in the road. And I see patients picking based on the wrong things. Their friends, you know, is on it, they saw a TikTok, their primary care doctor had a sample. That's not how to pick. The right pill for you depends on one question, really. What does your daily life actually look like? Because the lived experience of taking these is so different that the molecule almost stops being the point. Adherence is the point. Five shots. Chemistry, dosing, weight loss, side effects, cost. Then I'll tell you exactly which pill I write for which patient. Shot one, the chemistry. Foundayo and oral wagove are not just different brand names, they are different kinds of drugs. Oral wagovi is semaglutide, a peptide, so that's a chain of amino acids that mimics your natural GLP1 hormone. Peptides have one big problem stomach acid destroys them. An enzyme called pepsin tears them apart on contact. That is why every GLP1 for the last 20 years has been an injection. So how did Novo Nordisk make a pill virgin? Well, they paired it with an absorption enhancer called SNAC. SNAC buffers the pH around the pill so the acid doesn't destroy the drug. It keeps the semaglutide molecules from clumping and it temporarily makes the cells of your stomach lining permeable so the drug can slip through into the bloodstream. Even with all that engineering, bioavailability is only about 0.8%. About one in 125 molecules you swallow makes it into your blood. The 25 milligram tablet ends up producing blood levels comparable to a 0.5 to 1 milligram subcutaneous injection. Once it's in your blood, it acts identically to the shot. Foundeo is a completely different story. Or forglipron is not a peptide. So it's a small molecule, a different category of compound entirely. It's designed from scratch to bind the GLP1 receptor. Because it's not a peptide, stomach acid doesn't destroy it. No snack needed, no absorption enhancer, no food restrictions or water restrictions or timing windows. Per the FDA label, you can swallow Foundaleo any time of day, with or without food, you know, with whatever beverage you prefer. It is the first small molecule GLP1 receptor agonist ever approved. So two pills, same target, two completely different keys, and the chemistry is what determines everything that comes next. Shot two, the dosing rules. So both medications use a slow titration ladder. That part is roughly the same. Found AO first. So six dose strengths from 0.8 milligrams up to a max dose of 17.2. Step up is monthly. So the ritual, take it. Any time of day with food, even without, etc. Swallow it whole, don't split or crush it. That is literally the entire instruction set. Now for oral wagovy, uh five dose strengths from 1.5 up to 25 milligram maintenance dose, same monthly titration. Here's what patients on Reddit have nicknamed the Wagovi ritual. And listen carefully because every piece of it does matter. One, take it first thing in the morning, completely empty stomach. Two, with no more than four ounces, about half a cup of plain water, not coffee, not juice, plain water. Three, wait at least 30 minutes before eating, drinking, anything else, or taking any other oral medications. Four, swallow whole every single day. And patients ask me, you know, come on, is it really that strict? And the answer is yes. The data is not subtle. So take it with food, drug absorption is severely reduced or actually completely absent. Wash it down with a glass of water, you get about 70% less drug exposure than with two ounces. So skip the 30-minute wait you cut into your absorption window before the tablet has even finished eroding. Skip the ritual, and the medication does not work. That is not a best practice. That is the difference between absorbing the drug and not absorbing it at all. The chemistry built the ritual, and the ritual is what every patient has to live with every day for as long as they're on the drug. Shot three, weight loss data. So how much weight comes off? Both drugs had phase three trials in the New England Journal of Medicine in 2025. Different studies, different populations. There is no head-to-head, so the comparison is imperfect. But the headline numbers are clear. Attain one was the Foundado trial, 3,127 adults with obesity, no diabetes. They were treated for 72 weeks at the highest dose, 17.2 milligrams. Patients lost 12.4% of body weight. That's about 27 pounds. Now mid-dose, around 10.8%, low dose, 7.5. Placebo, less than 1%. The DEXA body comp data showed about 73% of the weight loss was fat mass and 27% was lean. So right in line with the rest of the GLP1 class. Oasis 4 was the oral Wagovi trial. It was smaller, 307 adults, treated for 64 weeks. At the end, patients on the pill lost 13.6% of body weight. Placebo lost 2.2. 30% of the treatment group lost 20% or more. And here's the part I want you to hear. 13.6% is comparable to what injectable Wagovi 2.4 milligrams produced in the original step one trial. So same molecule, same mechanism, similar result. The pill is the injection, just slower and harder to take correctly. Stack them head to head. Oral Wagovie, 13.6% at 64 weeks. Foundo 12.4% at 72 weeks. So a 1.2% point gap, that's roughly 3 to 4 pounds of difference for a typical patient spread across more than a year. The gap is small enough that adherence probably matters as much as the molecule. A patient who takes oral wagovi correctly six days a week and breaks the ritual on the seventh isn't getting 13.6%. They're getting whatever absorption their actual habits allow. A patient who takes Foundayo every day with breakfast, no thinking required, gets the full 12.4. The trial number is the ceiling. The ritual is what determines whether you actually get there. SHOT 4. The side effect paradox. So both drugs activate the same receptor. So both produce the same family of gastrointestinal side effects. Nausea, vomiting, diarrhea, constipation, dyspepsia. Most cluster during dose escalation and plateau once you reach a stable dose. And critically, GI side effects are not the mechanism of weight loss. Patients who get sick and patients who do not lose essentially the same amount of weight. So feeling terrible is not why these drugs work. There is a stubborn myth out there that you have to suffer for these to work, and that's just wrong. And now here's the paradox nausea. Foundeo, you know, at the top dose, 33.7%, oral wagovy 25, 46.6%, vomiting, found 24%, oral wagovy 30.9%. So by that math, foundo looks easier on the gut. But discontinuation rate. The number of patients who stopped because of side effects. Foundeo at the top dose 10.3%, oral Wagovi 25, 6.9%. So more Foundeo patients quit. How? Foundeo's GI side effects are steeply dose dependent. At the lowest trial dose, nausea was around 29% and discontinuation was about 5%. Much gentler. In real-world practice, a lot of patients aren't going to need the max 17.2 milligram dose, and plenty land in the 5.5 to 9 milligram range and stay there because that's where they're gonna they're losing weight. That's the golden rule. Like it always does, it you know, it works on these meds. The the dose that works is the right dose. There is no metal for getting to the top of the ladder if you don't need to. Oral wagove doesn't have that gradient. The 25 milligram maintenance dose is where you're probably going to live. The 46.6% nausea figure is the realistic expectation, not a worst case. So here's the honest framing. Oral wagovi is harder on the gut, more consistently, for the duration of treatment. FoundAo can be harder at the very top dose, but a lot of patients don't need to go there. If you like this depth of coverage on GLP1s, head to BarrickHealth.com and pre-order the GLP1 Bible. It's the most comprehensive book on GLP1s and weight loss ever written. Release date is just a few weeks away. Lock in the pre-order price now. Back to the episode. SHOP 5. What'll you pay? Cost used to be the easy differentiator, but not anymore. Both manufacturers have learned hard or leaned hard into direct-to-consumer pricing. As of mid-2026, self-pay through the manufacturer of pharmacies is the rational default for most patients without strong insurance. And let's be honest, that's most of us. Foundaleo through LilyDirect starting dose is$149 a month. Step two,$199, and then from 5.5 milligrams up to that max 17.2 is going to run you$299 a month. With commercial insurance and the Lily savings card, eligible patients can get as low as$25 a month. Oral Wagovi through Novicare, starting dose$149, so same as Foundaleo. Same trajectory through titration. So maintenance dose is$299 a month with commercial insurance and the savings card, eligible patients dropping down to about$25 per month. So cost is no longer a meaningful differentiator between these two pills. Both walk you from$149 to$299. Both can hit$25 with good insurance and a savings card. The decision is about how the medication fits your life, not what it costs. Here's the straight shot. This is what I tell my patients. FoundAo trades a little bit of efficacy for convenience. Oral Wagovy trades that convenience for a little more efficacy. Neither is universally better. The right one depends on what you can actually do every single day. Pick oral Wagovi if you can build the morning ritual into your life reliably. Wake up, swallow, set up a 30-minute timer, do your morning routine while you wait. So if that sounds doable, you're a great candidate. Pick it if you want max weight loss from a pill. And pick it if you have true needle phobia and an injectable is genuinely off the table. That is the number one reason I write oral Wagovi. Not patients who prefer a pill, patients who cannot use a needle. Big difference. Pick foundale if the morning fasting window genuinely will not work in your life. Shift workers, parents with kids who you know eat breakfast at 5 a.m., frequent travelers, patients on levo thyroxine for thyroid, patients who need that coffee in their hand the second their you know feet hit the floor, that's me for sure. Pick it if you're switching off an injectable for low friction maintenance. And one important reframe: if you can already tolerate injections and you want max weight loss, neither pill is your best option. Truzepatite injection still produces around 20% weight loss. You know, that's in the from the surmount trials. The oral pill conversion, you know, is for patients who cannot or will not inject. Do not pick a pill just because it's a pill, if a needle would actually serve you better. The right pill is the one you'll actually take every day the way it's meant to be taken. That's not a hedge, that's the entire decision. That's your side by side. Fondeo, the easy pill, around 12% weight loss, no rules. Oral Wagovi, the strict pill, around 14%, build the ritual. If you got value out of this, share it with someone who's trying to decide. There's a lot of bad takes online from which pill is quote unquote better. The honest answer is neither until you know which one fits your life, the way you actually live. Want a doctor with the time to walk you through this one on one? That's what I built at Barrack Health. Visit BarrackHealth.com and set up a free consult. I'm Dr. Cleet Barrack. This was Straight Shot. We'll catch you again soon.